Back to results
US 7,410,955 B2Granted
Therapeutic use of agonist ligands specific to G2A receptor
AssigneeBiosynergen, Inc.
InventorsYung-Hi Kim, Dong-Keun Song, Hong-Won Suh, Sung-Oh Huh
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBiosynergen, Inc.
InventorsYung-Hi Kim, Dong-Keun Song, Hong-Won Suh, Sung-Oh Huh
Estimating the term…
The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.
A method for treating sepsis or septic shock comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of 18:0 LPC (1-stearoyl lysophosphatidylcholine), 18:1 LPC (1-oleoyl lysophosphatidylcholine), 14:0 LPC (1-myristoyl lysophospatidylcholine), 16:0 LPC (1-palmitoyl lysophosphatidylcholine) and SPC (sphingosylphosphorylcholine).
Dependencies are inferred from the claim text.